Serum glycan signatures of gastric cancer

Cancer Prevention Research

Volumn 7, Issue 2, 2014, Pages 226-235

  Ozcan, Sureyya ^a   Barkauskas, Donald A ^c   Ruhaak, L Renee ^a   Torres, Javier ^d   Cooke, Cara L ^a   An, Hyun Joo ^e   Hua, Serenus ^e   Williams, Cynthia C ^a   Dimapasoc, Lauren M ^a   Kim, Jae Han ^e   Camorlinga Ponce, Margarita ^d   Rocke, David ^a,b   Lebrilla, Carlito B ^a   Solnick, Jay V ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California Davis   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e Chungnam National University   (South Korea)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CARBOHYDRATE SEQUENCE; CASE-CONTROL STUDIES; FEMALE; GLYCOSYLATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MALE; METABOLOME; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; SEROEPIDEMIOLOGIC STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893863877     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0235     Document Type: Article

References (73)

1. Fuchs CS, Mayer RJ. Medical progress-gastric-carcinoma. NewEngl J Med 1995;333:32-41.
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hemat 2005;54:209-41.
3. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma-review and considerations for future directions. Ann Surg 2005;241:27-39.
4. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
5. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
6. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Mic Sc 1965;64: 31-49.
7. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterol 2007;133:659-72.
8. Marshall B, Warren J. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;i: 1311-5.
9. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
10. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 2008;105:1003-8.
11. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterol 1998;115:642-8.
12. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-8.
13. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastriccarcinoma. New Engl J Med 1991;325:1127-31.
14. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. Cancer statistics review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2009.
15. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009;7:887-94.
16. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007;42:2-10.
17. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006;9:245-53.
18. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
19. Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, et al. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2006;15:1341-7.
20. Swami M. Proteomics: a discovery strategy for novel cancer biomarkers. Nat Rev Cancer 2010;10:597.
21. Reymond MA, Schiegel W. Proteomics in cancer. Adv Clin Chem 2007;44:103-42.
22. Tabares G, Radcliffe CM, Barrabes S, Ramirez M, Aleixandre RN, Hoesel W, et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006;16:132-45.
23. Wada Y, Azadi P, Costello CE, Dell A, Dwek RA, Geyer H, et al. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology 2007;17:411-22.
24. Abd Hamid UM, Royle L, Saldova R, RadcliffeCM, Harvey DJ, Storr SJ, et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008;18:1105-18.
25. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat Methods 2005;2:817-24.
26. Kolarich D, Lepenies B, Seeberger PH. Glycomics, glycoproteomics and the immune system. Curr Opin Chem Biol 2012;16:214-20.
27. Amano M, Nishimura SI. Large-scale glycomics for discovering cancer-associated N-glycans by integrating glycoblotting and mass spectrometry. Method Enzymol 2010;478:109-25.
28. Taniguchi N. Toward cancer biomarker discovery using the glycomics approach. Proteomics 2008;8:3205-8.
29. Arnold JN, Saldova R, Galligan MC, Murphy TB, Mimura-Kimura Y, Telford JE, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res 2011;10:1755-64.
30. An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li BS, Lam KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res 2006;5:1626-35.
31. Kirmiz C, Li BS, An HJ, Clowers BH, Chew HK, Lam KS, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics 2007;6:43-55.
32. Leiserowitz GS, Lebrilla C, Miyamoto S, An HJ, Duong H, Kirmiz C, et al. Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int J Gynecol Cancer 2008;18:470-5.
33. Zaia J. Mass spectrometry and glycomics. Omics 2010;14:401-18.
34. Zaia J. Mass spectrometry and the emerging field of glycomics. Chem Biol 2008;15:881-92.
35. Turner GA. N-glycosylation of serum proteins in disease and its investigation using lectins. Clin Chim Acta 1992;208:149-71.
36. An HJ, Ninonuevo M, Aguilan J, Liu H, Lebrilla CB, Alvarenga LS, et al. Glycomics analyses of tear fluid for the diagnostic detection of ocular rosacea. J Proteome Res 2005;4:1981-7.
37. Franz AH, Molinski TF, Lebrilla CB. MALDI-FTMS characterization of oligosaccharides labeled with 9-aminofluorene. JAmSoc Mass Spectr 2001;12:1254-61.
38. Tseng K, Wang H, Hedrick JL, Lebrilla CB. The catalog approach to the complete structural elucidation of unknown neutral oligosaccharide alditols by MALDI-MS. Glycobiology 1998;8:1136-7.
39. Cancilla MT, Penn SG, Lebrilla CB. Alkaline degradation of oligosaccharides coupled with matrix-assisted laser desorption/ionization Fourier transform mass spectrometry: a method for sequencing oligosaccharides. Anal Chem 1998;70:663-72.
40. Vieira AC, An HJ, Ozcan S, Kim J-H, Lebrilla CB, Mannis MJ. Glycomic analysis of tear and saliva in ocular rosacea patients: the search for a biomarker. Ocul Surf 2012;10:184-92.
41. Ruhaak LR, Miyamoto S, Lebrilla CB. Glycomics analysis of dried blood spots. Glycobiology 2011;21:1531.
42. An HJ, Lebrilla CB. Structure elucidation of native N-and O-linked glycans by tandem mass spectrometry (tutorial). Mass Spectrom Rev 2011;30:560-78.
43. Hua S, An HJ, Ozcan S, Ro GS, Soares S, DeVere-White R, et al. Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst 2011;136: 3663-71.
44. de Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, et al. High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics 2011;10:M110.002717.
45. Dallas DC, Martin WF, Strum JS, Zivkovic AM, Smilowitz JT, Underwood MA, et al. N-linked glycan profiling of mature human milk by high-performance microfluidic chip liquid chromatography time-of-flight tandem mass spectrometry. J Agr Food Chem 2011;59:4255-63.
46. Kronewitter SR, de Leoz MLA, Peacock KS, McBride KR, An HJ, Miyamoto S, et al. Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling. J Proteome Res 2010;9:4952-9.
47. Chu CS, Ninonuevo MR, Clowers BH, Perkins PD, An HJ, Yin HF, et al. Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics 2009;9: 1939-51.
48. An HJ, Kronewitter SR, de Leoz MLA, Lebrilla CB. Glycomics and disease markers. Curr Opin Chem Biol 2009;13:601-7.
49. de Leoz MLA, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, et al. Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers 2008;25:243-58.
50. Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E, Herrero R, Bernal-Sahagun F, Abdo-Francis JM, et al. Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal Pathologies. Cancer Epidem Biomar 2008;17:2498-504.
51. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
52. Torres J, Perez-Perez GI, Leal-Herrera Y, Munoz O. Infection with CagA+ Helicobacter pylori strains as a possible predictor of risk in the development of gastric adenocarcinoma in Mexico. Int J Cancer 1998;78:298-300.
53. Kronewitter SR, De Leoz ML, Strum JS, An HJ, Dimapasoc LM, Guerrero A, et al. The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics 2012;12: 2523-38.
54. Barkauskas D. FTICRMS: programs for analyzing fourier transform-ion cyclotron resonance mass spectrometry data R package. 2012;version 0.9.
55. Barkauskas DA, Rocke DM. A general-purpose baseline estimation algorithm for spectroscopic data. Anal Chim Acta 2010;657:191-7.
56. Barkauskas DA, Kronewitter SR, Lebrilla CB, Rocke DM. Analysis of MALDI FT-ICR mass spectrometry data: a time series approach. Anal Chim Acta 2009;648:207-14.
57. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc B Met 1995;57:289-300.
58. Miller R. G. Simultaneous statistical inference. New York: Springer-Verlag; 1981.
59. Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013;24: 209-15.
60. Balog CI, Stavenhagen K, Fung WL, Koeleman CA, McDonnell LA, Verhoeven A, et al. N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics 2012;11:571-85.
61. Hoja-Lukowicz D, Ciolczyk D, Bergquist J, Litynska A, Laidler P. Highmannose-type oligosaccharides from human placental arylsulfatase A are core fucosylated as confirmed by MALDI MS. Glycobiology 2000; 10:551-7.
62. Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, White RWD, et al. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics 2009;25:251-7.
63. Hua S, Williams CC, Dimapasoc LM, Ro GS, Ozcan S, Miyamoto S, et al. Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. J Chromatogr A 2013;1279:58-67.
64. Ruhaak LR, Nquyen UT, Stroble C, Taylor SL, Taguchi A, Hanash S, et al. Enrichment strategies in glycomics based lung cancer biomarker development. Proteomics Clin Appl. 2013 May 3. [Epub ahead of print]
65. Kim YG, Jeong HJ, Jang KS, Yang YH, Song YS, Chung J, et al. Rapid and high-throughput analysis of N-glycans from ovarian cancer serum using a 96-well plate platform. Anal Biochem 2009;391:151-3.
66. Bones J, Mittermayr S, O'Donoghue N, Guttman A, Rudd PM. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem 2010;82:10208-15.
67. Bones J, Byrne JC, O'Donoghue N, McManus C, Scaife C, Boissin H, et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 2011; 10:1246-65.
68. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007;17: 1344-56.
69. Goetz JA, Mechref Y, Kang P, Jeng MH, Novotny MV. Glycomic profiling of invasive and non-invasive breast cancer cells. Glycoconj J 2009;26:117-31.
70. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 2006;66:5540-1.
71. Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 2012;29:57-66.
72. Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. The Biochem J 1989;259:347-53.
73. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.